In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Potassium canrenoate is a competitive antagonist of aldosterone receptor .
Aldosterone is a steroid hormone and plays an important role in the regulation of blood pressure by increasing reabsorption of ions and water in the kidney.
In cultured rat and human cells, potassium canrenoate produced genotoxic effects in a doce-dependant way .
In male Wistar rats injected with isoprenaline (400 mg/kg), heart and left ventricular weights increased significantly. While potassium canrenoate (20 mg/kg/day) relieved this increase. Potassium canrenoate significantly reduced the fibrosis induced by isoprenaline . In 30 essential hypertensives, canrenoate potassium reduced intraerythrocyte Na+ content and increased Na-K pump . In 15 patients with idiopathic primary aldosteronism, potassium canrenoate normalized the aldosterone/plasma renin activity (PRA) ratio .
. Bos R, Mougenot N, Médiani O, et al. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J Pharmacol Exp Ther, 2004, 309(3): 1160-1166.
. Martelli A, Mattioli F, Carrozzino R, et al. Genotoxicity testing of potassium canrenoate in cultured rat and human cells. Mutagenesis, 1999, 14(5): 463-472.
. Niutta E, Cusi D, Colombo R, et al. Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin. Am J Hypertens, 1988, 1(4 Pt 1): 364-371.
. Armanini D, Scaroni C, Mattarello MJ, et al. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest, 2005, 28(3): 236-240.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||insoluble in EtOH; insoluble in DMSO; ≥117.4 mg/mL in H2O|
|Shipping Condition||Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request.|
|General tips||For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.|